Showing results (1-10 of 45) with videos related to
Sort By:
Pageof 5
International Journal of Antimicrobial Agents|February 15, 2015
A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infectionsMichael W Dunne, Meijian Zhou, Borje DarpoAnnals of Clinical Microbiology and Antimicrobials|April 18, 2015
Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studiesMichael W Dunne, Dan Sahm, Sailaja PuttaguntaClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2015
A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure InfectionMichael W Dunne, Sailaja Puttagunta, Philip Giordano, et al.Clinical Drug Investigation|October 14, 2015
Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese SubjectsPatrick J Scoble, Robert C Owens, Sailaja Puttagunta, et al.Drug Safety|December 31, 2015
Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative StudiesMichael W Dunne, George H Talbot, Helen W Boucher, et al.Microbiology Spectrum|February 9, 2022
Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible EnterobacteralesMichael W Dunne, Sailaja Puttagunta, Steven I Aronin, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 1, 2022
Regional Differences in Antibiotic-resistant Enterobacterales Urine Isolates in the United States: 2018-2020Steven I Aronin, Vikas Gupta, Michael W Dunne, et al.BMC Infectious Diseases|March 1, 2022
A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011-2020Michael W Dunne, Steven I Aronin, Kalvin C Yu, et al.Journal of Global Antimicrobial Resistance|June 24, 2025
In vitro activity of sulopenem and comparator agents against US Enterobacterales clinical isolates collected during the SENTRY antimicrobial surveillance program in 2023Steven I Aronin, Michael D Huband, Holly Becker, et al.Antimicrobial Agents and Chemotherapy|May 20, 2015
In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance ProgramSandra P McCurdy, Ronald N Jones, Rodrigo E Mendes, et al.Pageof 5